Literature DB >> 21884010

Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.

Marco Bucci1, Ronald Borra, Kjell Någren, Jussi P Pärkkä, Silvia Del Ry, Romina Maggio, Helena Tuunanen, Tapio Viljanen, Manuela Cabiati, Sara Rigazio, Markku Taittonen, Uberto Pagotto, Riitta Parkkola, Lionel H Opie, Pirjo Nuutila, Juhani Knuuti, Patricia Iozzo.   

Abstract

INTRODUCTION: The metabolic modulator trimetazidine (TMZ) has been suggested to induce a metabolic shift from myocardial fatty acid oxidation (FAO) to glucose utilization, but this mechanism remains unproven in humans. The oxidation of plasma derived FA is commonly measured in humans, whereas the contribution of FA from triglycerides stored in the myocardium has been poorly characterized. AIMS: To verify the hypothesis that TMZ induces a metabolic shift, we combined positron emission tomography (PET) and magnetic resonance spectroscopy ((1)H-MRS) to measure myocardial FAO from plasma and intracellular lipids, and myocardial glucose metabolism. Nine obese subjects were studied before and after 1 month of TMZ treatment. Myocardial glucose and FA metabolism were assessed by PET with (18)F-fluorodeoxyglucose and (11)C-palmitate. (1)H-MRS was used to measure myocardial lipids, the latter being integrated into the PET data analysis to quantify myocardial triglyceride turnover.
RESULTS: Myocardial FAO derived from intracellular lipids was at least equal to that of plasma FAs (P = NS). BMI and cardiac work were positively associated with the oxidation of plasma derived FA (P ≤ 0.01). TMZ halved total and triglyceride-derived myocardial FAO (32.7 ± 8.0 to 19.6 ± 4.0 μmol/min and 23.7 ± 7.5 to 10.3 ± 2.7 μmol/min, respectively; P ≤ 0.05). These changes were accompanied by increased cardiac efficiency since unchanged LV work (1.6 ± 0.2 to 1.6 ± 0.1 Watt/g × 10(2), NS) was associated with decreased work energy from the intramyocardial triglyceride oxidation (1.6 ± 0.5 to 0.4 ± 0.1 Watt/g × 10(2), P = 0.036).
CONCLUSIONS: In obese subjects, we demonstrate that myocardial intracellular triglyceride oxidation significantly provides FA-derived energy for mechanical work. TMZ reduced the oxidation of triglyceride-derived myocardial FAs improving myocardial efficiency.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21884010     DOI: 10.1111/j.1755-5922.2011.00275.x

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  14 in total

Review 1.  Recent advances in metabolic imaging.

Authors:  Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

Review 2.  Fatty heart, cardiac damage, and inflammation.

Authors:  Maria A Guzzardi; Patricia Iozzo
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 3.  Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.

Authors:  Victor Soukoulis; William E Boden; Sidney C Smith; Patrick T O'Gara
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

Review 4.  Trimetazidine and Other Metabolic Modifiers.

Authors:  Giacinta Guarini; Alda Huqi; Doralisa Morrone; Paola Francesca Giuseppina Capozza; Mario Marzilli
Journal:  Eur Cardiol       Date:  2018-12

5.  Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up.

Authors:  Xiaohan Xu; Weijun Zhang; Yujie Zhou; Yingxin Zhao; Yuyang Liu; Dongmei Shi; Zhiming Zhou; Hanying Ma; Zhijian Wang; Miao Yu; Qian Ma; Fei Gao; Hua Shen; Jianwei Zhang
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

6.  Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.

Authors:  John R Ussher; Wendy Keung; Natasha Fillmore; Timothy R Koves; Jun Mori; Liyan Zhang; David G Lopaschuk; Olga R Ilkayeva; Cory S Wagg; Jagdip S Jaswal; Deborah M Muoio; Gary D Lopaschuk
Journal:  J Pharmacol Exp Ther       Date:  2014-04-03       Impact factor: 4.030

Review 7.  (1)H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism.

Authors:  Kiterie M E Faller; Craig A Lygate; Stefan Neubauer; Jürgen E Schneider
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

8.  [Effect of trimetazidine on cardiac function and exercise tolerance in hypertension patients with diabetic].

Authors:  Pingxian Ye; Pingzhen Ye; Jinping He
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-05-25

9.  Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus.

Authors:  Drazenka Jankovic; Yvonne Winhofer; Miriam Promintzer-Schifferl; Evelyne Wohlschläger-Krenn; Christian Heinz Anderwald; Peter Wolf; Thomas Scherer; Gert Reiter; Siegfried Trattnig; Anton Luger; Michael Krebs; Martin Krssak
Journal:  PLoS One       Date:  2012-12-03       Impact factor: 3.240

10.  Seeing is believing: dietary fatty acids hurry up from the stomach to the heart of patients with impaired glucose tolerance.

Authors:  Patricia Iozzo
Journal:  Diabetes       Date:  2012-11       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.